UCSD Profiles
search, discover, network

Teresa Helsten

Title	Associate Clinical Professor
School	University of California, San Diego
Department	Medicine
Address	9300 Campus Point Drive #7329 CA La Jolla 92037
Phone	858-249-3249
vCard	Download vCard

Overview

Research Interests
Dr. Helsten focuses first and foremost on providing excellent care for breast cancer patients. She provides neoadjuvant, adjuvant, and metastatic treatments, including endocrine therapy, chemotherapy, and targeted therapies. She actively enrolls patients to clinical trials.

Dr. Helsten’s research is primarily focused on clinical trials chosen to bring the most cutting edge care to her patients. She runs several clinical trials and enrolls patients to these and cooperative group and investigator initiated trials at UCSD. She is a coinvestigator of the groundbreaking I-SPY 2 study (www.ispy2.org). She is actively engaged in the design and implementation of translational research projects in breast cancer. FGFR inhibitors are of particular interest.

Education and Training
BS - Chemistry, Massachusetts Institute of Technology - 1990
MD - University of California, Davis - 1998
Resident - Harbor-UCLA Medical Center - 1998-2001
Chief Resident - Harbor-UCLA Medical Center - 2001-2002
Oncology Fellowship - UC San Diego Medical Center - 2002-2005

Interests

Medical oncology, Breast cancer, Clinical Trials, FGFR, Fibroblast growth factor, Fibroblast growth factor receptor

ORNG Applications

Websites

Bibliographic

Publications

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.

List All | Timeline

Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22. PMID: 27406346.

View in: PubMed
Helsten T, Kato S, Schwaederle M, Tomson BN, Buys TP, Elkin SK, Carter JL, Kurzrock R. Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics. Mol Cancer Ther. 2016 Jul; 15(7):1682-90. PMID: 27196769.

View in: PubMed
Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten T, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther. 2016 Apr; 15(4):743-52. PMID: 26873727.

View in: PubMed
Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten T, Lippman SM, Parker BA, Kurzrock R. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. 2015 Oct 20; 6(32):32602-9. PMID: 26418953; PMCID: PMC4741715.

View in: PubMed, PubMed Central
Kato S, Elkin SK, Schwaederle M, Tomson BN, Helsten T, Carter JL, Kurzrock R. Genomic landscape of salivary gland tumors. Oncotarget. 2015 Sep 22; 6(28):25631-45. PMID: 26247885; PMCID: PMC4694855.

View in: PubMed, PubMed Central
Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clin Cancer Res. 2016 Jan 01; 22(1):259-67. PMID: 26373574.

View in: PubMed
Helsten T, Schwaederle M, Kurzrock R. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. Cancer Metastasis Rev. 2015 Sep; 34(3):479-96. PMID: 26224133; PMCID: PMC4573649.

View in: PubMed, PubMed Central
Parker BA, Schwaederlé M, Scur MD, Boles SG, Helsten T, Subramanian R, Schwab RB, Kurzrock R. Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center. J Oncol Pract. 2015 Nov; 11(6):442-9. PMID: 26243651.

View in: PubMed
Parish A, Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, Shimabukuro K, Parker BA, Helsten T, Kurzrock R. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. Cell Cycle. 2015; 14(13):2121-8. PMID: 25950492; PMCID: PMC4614941.

View in: PubMed, PubMed Central
Scott BJ, van Vugt VA, Rush T, Brown T, Chen CC, Carter BS, Schwab R, Fanta P, Helsten T, Bazhenova L, Parker B, Pingle S, Saria MG, Brown BD, Piccioni DE, Kesari S. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. J Neurooncol. 2014 Sep; 119(2):361-8. PMID: 24942463.

View in: PubMed
Costantini C, Ale-Ali A, Helsten T. Sleep aid prescribing practices during neoadjuvant or adjuvant chemotherapy for breast cancer. J Palliat Med. 2011 May; 14(5):563-6. PMID: 21388255.

View in: PubMed
Helsten T, Bunch TA, Kato H, Yamanouchi J, Choi SH, Jannuzi AL, Féral CC, Ginsberg MH, Brower DL, Shattil SJ. Differences in regulation of Drosophila and vertebrate integrin affinity by talin. Mol Biol Cell. 2008 Aug; 19(8):3589-98. PMID: 18508915; PMCID: PMC2488300.

View in: PubMed, PubMed Central
Bunch TA, Helsten T, Kendall TL, Shirahatti N, Mahadevan D, Shattil SJ, Brower DL. Amino acid changes in Drosophila alphaPS2betaPS integrins that affect ligand affinity. J Biol Chem. 2006 Feb 24; 281(8):5050-7. PMID: 16371365.

View in: PubMed